The state of New Jersey currently has 101 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Breast Cancer
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +10 locations
Conditions: Breast Cancer
Register for Updates
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT06678269
Recruiting
The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey +2 locations
Conditions: Metastatic Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Breast Cancer Metastatic, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Hormone-receptor-positive Breast Cancer
Register for Updates
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
NCT05570253
Recruiting
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +3 locations
Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer
Register for Updates
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
NCT05716893
Recruiting
In this study, investigators will compare standard Aerobic Training/AT with adaptive Aerobic Training/AT. Standard AT will be a fixed (unchanging) amount of walking each week, while adaptive AT will adjust the level of exercise depending on participants' response to the exercise. Investigators will see how both study approaches (standard AT and adaptive AT) affect participants' CRF.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Breast Cancer, Breast Carcinoma
Register for Updates
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT05256745
Recruiting
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Register for Updates
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03808337
Recruiting
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +2 locations
Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Register for Updates
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT06144164
Recruiting
The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/16/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Breast Cancer, Breast Carcinoma, Female Breast Cancer
Register for Updates
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT06246968
Recruiting
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Summit Medical Group Eastside Clinic,1 Diamond Hill Road, Berkeley Heights, New Jersey +12 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438
Recruiting
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Register for Updates
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
Recruiting
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: John Theurer Cancer Ctr at Hackensack Univ. Med Ctr., Hackensack, New Jersey
Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Register for Updates